EmeritusDX Launches Advanced Hematopathology Services, Expanding Rapidly Growing Test Portfolio

▤ Summary

EmeritusDX launched new hematopathology services for hematologist-oncologists and patients across the U.S. The offering expands the company’s cancer diagnostics portfolio beyond solid tumors into blood-related malignancies. EmeritusDX combines its Synatra case assessment platform with flow cytometry, FISH, molecular testing, cytogenetics, and NGS to deliver more precise diagnostic and prognostic insights. The company says the program improves turnaround times, supports urgent cases within 24 hours, and gives physicians direct access to hematopathologists. EmeritusDX also highlights partnerships with hospitals, labs, biotech firms, academic institutions, CROs, and pharmaceutical companies.

▦ Linked Companies